Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.

ABSTRACT:

Objective

To assess the cost-effectiveness of pembrolizumab in combination with chemotherapy compared to chemotherapy alone, based on the results of the NRG-GY018 trial, in patients with advanced or recurrent endometrial cancer (EC), stratified by mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) subgroups.

Methods

A Markov model was used to simulate patients receiving either pembrolizumab plus chemotherapy or chemotherapy alone. Lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were calculated using a willingness-to-pay (WTP) threshold of $150,000/QALY. Univariate and probabilistic sensitivity analyses were conducted to assess the robustness of our findings.

Results

The addition of pembrolizumab

SUBMITTER: Huo G 

PROVIDER: S-EPMC11543263 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature